https://doi.org/10.55788/49f9ef2d
This first-in-human prospective, multicentre trial (NCT05144503, NCT05115214) assessed the safety, performance, and effectiveness of treating paroxysmal AF using a conformable pulmonary vein isolation catheter [1]. Using this conformable catheter with a shape-adaptive design, mapping and radiofrequency ablation can be performed in 1 procedure.
Participants were included if they had at least 2 documented ECG episodes of AF within 1 year of enrolment and recurrent, self-terminating AF, as well as failure or intolerance to at least 1 class I–IV anti-arrhythmic drug. A total of 85 patients were enrolled and treated, including 35 patients in the highest waveform cohort PULSE3.
At 1 year, 81.8% (95% CI 70.2–89.2) of the participants were arrhythmia-free in the total cohort, while in the PULSE3 cohort, this rate was 100% (95% CI 80.6–100). One patient (1.2%) had a serious adverse event of diplopia and vertigo (remission within 2 days). MRI analyses of the oesophagus showed minor erythaema, injury to the mucosa, and post-anaesthesia intubation irritation in 1 patient each; however, only the latter was considered procedure-related.
Remapping at day 75 post-ablation showed an increase in durability, with increasing pulse waveform reaching almost 100% in the PULSE3 cohort. “In this first-in-human study, the conformable pulsed field ablation catheter was efficacious, safe, and clinically effective for performing pulmonary vein isolation, and created durable lesions,” concluded Prof. Vivek Reddy (Icahn School of Medicine at Mount Sinai, NY, USA). However, the efficacy of this catheter is currently unknown in other lesion sets or other populations, such as patients with non-paroxysmal AF.
- Reddy VY, et al. First-in-human clinical series of a novel conformable "single-shot" pulsed field ablation catheter for pulmonary vein isolation. Late-Breaking Science: ablation. EHRA Congress 2024, 7–9 April, Berlin, Germany.
Copyright ©2024 Medicom Medical Publishers
Posted on
Previous Article
« AF burden versus classical AF classification in predicting arrhythmia recurrence Next Article
MRI head-to-head comparison of lesion quality following various ablation techniques »
« AF burden versus classical AF classification in predicting arrhythmia recurrence Next Article
MRI head-to-head comparison of lesion quality following various ablation techniques »
Table of Contents: EHRA 2024
Featured articles
PIRECNA: Cardioneuroablation is feasible for vagally-induced atrioventricular block
ARTESiA: Stroke risk unaffected by subclinical atrial fibrillation duration
Personalising Ablation Techniques
Ablate-by-LAW: CT-determined left atrial wall thickness for ablation titration in atrial fibrillation
Personalised LAWT-guided ablation non-inferior to CLOSE protocol for paroxysmal atrial fibrillation
Style-AF: Improved outcomes with vascular closure versus figure-of-eight suture
Advantage of PREVENTIVE ablation plus implantable cardioverter-defibrillator in ischaemic cardiomyopathy
ASTRO AF: No benefit of staged left atrial appendage isolation cryoballoon ablation over radiofrequency ablation
Innovative Ablation Strategies
Pulsed-field ablation vs high-power short-duration radiofrequency in paroxysmal AF
CryoCure-VT: Endocardial ultra-low temperature cryoablation effective in sustained monomorphic ventricular tachycardia
PIRECNA: Cardioneuroablation is feasible for vagally-induced atrioventricular block
MRI head-to-head comparison of lesion quality following various ablation techniques
“Single-shot” conformable catheter shows promising efficacy in paroxysmal atrial fibrillation
Post-Ablation Recurrence
AF burden versus classical AF classification in predicting arrhythmia recurrence
ARTESiA: Stroke risk unaffected by subclinical atrial fibrillation duration
Ablation strategy and the number of repeat procedures not associated with atrial fibrillation recurrence
Factors associated with negative outcomes in post-operative atrial fibrillation
Arrhythmia Technologies
Smartphone rhythm monitoring optimises AF management following cardiac surgery
SMART-AV and SMART-CRT: Improved cardiac outcomes with algorithm-adapted atrioventricular delay
Premature battery depletion can affect a quarter of subcutaneous cardioverter defibrillators
New atrial fibrillation associated with a high risk of major cardiovascular outcomes
Related Articles
October 30, 2023
Catheter ablation saves lives in end-stage HF with AF
January 25, 2022
Jury still out on value of screening for atrial fibrillation
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com